Dongrui Pharmaceuticals (02348.HK) announces its interim results with a net profit attributable to the parent company's owners of approximately 105 million yuan, a decrease of 78.79% year-on-year.

The Zhitsu Finance and Economics APP reported that Dongrui Medicines (02348.HK) announced its mid-year performance for 2025, with revenue of approximately 630 million yuan, a year-on-year increase of 9.2%; gross profit of approximately 314 million yuan, a year-on-year decrease of 7.1%; net profit attributable to the parent company of approximately 105 million yuan, a year-on-year decrease of 78.79%; earnings per share of 0.06961 yuan, and a mid-year dividend per share of 0.015 Hong Kong dollars.